Literature DB >> 1030315

Two three-month treatment regimens for pulmonary tuberculosis.

B Kreis, S Pretet, J Birenbaum, P Guibout, J J Hazeman, E Orin, S Perdrizet, J Weil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1030315

Source DB:  PubMed          Journal:  Bull Int Union Tuberc        ISSN： 0074-9249


× No keyword cloud information.
  20 in total

1.  Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.

Authors:  Rovina Ruslami; Hanneke Nijland; Rob Aarnoutse; Bachti Alisjahbana; Arto Yuwono Soeroto; Suzanne Ewalds; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 3.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 4.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

5.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

6.  Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation.

Authors:  Zili Wang; Jiandang Shi; Guangqi Geng; Hongyan Qiu
Journal:  Eur Spine J       Date:  2012-10-11       Impact factor: 3.134

Review 7.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 8.  Cost effectiveness of antituberculosis interventions.

Authors:  A Castelo; P A Mathiasi; R Iunes; A L Kritski; M Dalcolmo; F Fiuza de Melo; M Drummond
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

Review 9.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

10.  Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Authors:  Rovina Ruslami; Hanneke M J Nijland; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.